INT-767

INT-767

I656576-1ml

1ml

10mM in DMSO

干燥,-80℃储存

超低温冰袋运输

INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC 50 s of 30 and 630 nM, respectively. In Vitro INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go -related gene potassium channel. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo INT-767 (10-20 mg/kg; i.p.; daily for 2 weeks) decreases plasma total cholesterol and triglyceride levels in db/m and db/db mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male 8-week old C57BKS/J db/db mice, control nondiabetic db/m miceDosage: 10, 20 mg/kg Administration: Intraperitoneal injection; daily for 2 weeks Result: Decreased plasma total cholesterol and triglyceride levels.

INT-767 是一种法尼类固醇 X 受体 (FXR)/TGR5 双激动剂，其平均 EC 50 s 分别为 30 和 630 nM。

1000403-03-1(DMSO)

C25H43NaO6S

494.66 g/mol

CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCOS(=O)(=O)[O-])C)C)O.[Na+]